To the editor: Regarding the exorbitant price of Harvoni, the new hepatitis C drug, David Lazarus writes that it costs $95,000 for a course of treatment. This is misleading. ("Here's why drugmakers are held in low esteem," column, Aug. 28)
Most insurance companies have negotiated with Gilead Sciences, the drug's maker, for, on average, a price 46% lower than list, according to the company. It costs even less for people who need only eight weeks of treatment.